Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50

Journal of the American Heart Association

Volumn 5, Issue 7, 2016, Pages

  Kidd, Stephen K ^a   Bonaca, Marc P ^a   Braunwald, Eugene ^a   De Ferrari, Gaetano M ^b,c   Lewis, Basil S ^d   Merlini, Piera A ^e   Murphy, Sabina A ^a   Scirica, Benjamin M ^a   White, Harvey D ^f   Morrow, David A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Atherosclerosis; Cardiovascular disease; Myocardial infarction; Platelet inhibitor

Indexed keywords

VORAPAXAR; ANTITHROMBOCYTIC AGENT; LACTONE; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOLOGY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TRANSIENT ISCHEMIC ATTACK; CLASSIFICATION; CORONARY ARTERY DISEASE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION;

AGED; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SECONDARY PREVENTION;

EID: 85019227278     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.003237     Document Type: Article

References (16)

1. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KAA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJO, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404–1413.
2. Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KAA, Murphy SA, Nicolau JC, Oude Ophuis T, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015;4:e001505 doi: 10.1161/JAHA.114.001505.
3. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
4. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50:2173–2195.
5. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Circulation. 2012;126:2020– 2035.
6. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P). Am Heart J. 2009;158:335–341.
7. Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, O’Donoghue ML, Murphy SA, Morrow DA. Coronary stent thrombosis with vorapaxar versus placebo results from the TRA 2°P-TIMI 50 trial. J Am Coll Cardiol. 2014;64:2309– 2317.
8. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/ European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38. Circulation. 2012;125:577– 583.
9. Scirica B, Morrow D, Antman E, Bonaca M, Murphy S, Braunwald E, Wiviott S. Timing and clinincal setting of cardiovascular death or myocardial infarction following PCI for ACS—observations from the Triton-TIMI 38 trial. J Am Coll Cardiol. 2012;59:E340–E340.
10. Cavender MA, Gibson CM, Braunwald E, Wiviott SD, Murphy SA, Toda Kato E, Plotnikov AN, Amuchastegui M, Oude Ophuis T, van Hessen M, Mega JL. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2—TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. 2014;4:468–474.
11. Leonardi S, Tricoci P, White HD, Armstrong PW, Huang Z, Wallentin L, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Providencia L, Nordrehaug JE, Held C, Strony J, Rorick TL, Harrington RA, Mahaffey KW. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA.CER) trial. Eur Heart J. 2013;34:1723–1731.
12. Sandoval Y, Smith SW, Thordsen SE, Apple FS. Supply/demand type 2 myocardial infarction: should we be paying more attention? J Am Coll Cardiol. 2014;63:2079–2087.
13. Morrow DA, Wiviot SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCab CH, Antman EM, Braunwald E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2009;19: 2758–2764.
14. Alpert JS, Thygesen KA, White HD, Jaffe AS. Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. Am J Med. 2014;127:105–108.
15. Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458–2473.
16. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation. 2006;114:1070–1077.